Method for Microbiome-Based Prediction, Diagnosis, and Treatment of Relapsing

  • Yeda
  • From Israel
  • Responsive
  • Patents for licensing

Summary of the technology

A novel method for analyzing the likelihood of weight regain following a weight loss program and maintaining target body weight, based on gut microbiome analysis.


Background and Unmet Need

The past century has seen an overwhelming increase in the prevalence of overweight and obese individuals, effecting over a third of the world’s population today. Obesity is strongly associated with conditions such as stroke, diabetes, high blood pressure, musculoskeletal disorders, and ischemic heart disease, the latter being considered a leading cause of overall mortality.
Despite continuous efforts to find a solution for the obesity epidemic, no dietary approach has been able to maintain prolonged weight reduction after the initial weight loss. Moreover, the recurrent weight gain usually exceeds that of the pre-weight loss intervention, irrespective of fitness level or genetic background. The health risks are further increased with each weight gain-loss cycle.
Consequently, there is a strong need for the development of novel methods for weight loss and more importantly, for stopping relapsing obesity post-weight loss intervention.

The Solution

The teams of Profs. Elinav and Segal have developed a method for analyzing the gut microbiome and inferring the likelihood of weight regain from the presence/absence of specific microbes.

Technology Essence

The Elinav-Segal research teams discovered that the amount and composition of certain microbes in the gut contribute to accelerated post-dieting weight regain. Therefore, down regulating certain microbes that are associated with weight gain while simultaneously upregulating microbes associated with weight loss can help achieve and maintain the target weight. The developed method consists of:
Treating the individual with a dieting aid.
Monitoring the amounts of different gut microbes indicative of weight gain/loss.
Administering an agent that alters the gut microbiome signature to that it will resemble the microbiome signature of
non-obese individuals.
The researchers have developed a personalized machine-learning algorithm, which based on the gut microbiome population, can predict the likelihood of recurrent weight gain (Fig 1.). Additionally, the researchers have tested different agents such as antibiotics, flavanoids, and fecal transplants in mouse models, to directly modulate the gut microbiome to avoid relapsing obesity.

Applications and Advantages

  • Diagnostic test for populations more susceptible to relapsed obesity
  • A potential method to reduce relapsed obesity by altering gut microbiome composition

Development Status

The teams of Profs. Elinav and Segal have developed a personalized machine-learning algorithm enabling microbiome based prediction of relapsing weight gain and have demonstrated in mice that fecal transplantation and post-biotic intervention may prevent excessive secondary weight gain. This research has been published in the prestigious scientific journal of Nature1.
Relevant Publications: Thaiss CA et al. Nature. 2016 [1]1

Intellectual property status

  • Granted Patent
  • Patent application number :USA Published: Publication Number: 2021-0260139-A1

Related Keywords

  • Biological Sciences
  • Medicine, Human Health
  • Clinical Research, Trials
  • Medical Research
  • Biology / Biotechnology
  • Diagnostic

About Yeda

Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world.

WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.

Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education.

Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta.

Yeda performs the following activities:

◣ Identifies and assesses research projects with commercial potential.
◣ Protects the intellectual property of WIS and its scientists.
◣ Licenses WIS' inventions and technologies to industry.
◣ Establishes new Startup companies based in WIS Intellectual Property
◣ Channels funding from industry to research projects.

Our portfolio covers a broad spectrum of the natural sciences, including:

◣ Agriculture and Plant Genetics, including Bio-fuels
◣ Chemistry and Nanotechnology
◣ Environmental Sciences and Solar Energy
◣ Mathematics and Computer Science
◣ Medical Devices
◣ Pharmaceuticals and Diagnostics
◣ Physics and Electro-Optics
◣ Research Tools


Never miss an update from Yeda

Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide


Send a request for information
to Yeda

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support